Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer

British Journal of Cancer

Volumn 99, Issue 7, 2008, Pages 1096-1102

  Huang, Y F ^a   Shen, M R ^a,b   Hsu, K F ^a   Cheng, Y M ^a   Chou, C Y ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cervical cancer; Cervical carcinoma; IGF binding protein 3; Insulin like growth factor 1; Insulin like growth factor 1 receptor

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN RECEPTOR; SQUAMOUS CELL CARCINOMA ANTIGEN;

ARTICLE; AUTOCRINE EFFECT; BLOOD LEVEL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PARACRINE SIGNALING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UTERINE CERVIX CANCER;

FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 53049087091     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604661     Document Type: Article

References (37)

1. Bae SN, Namkoong SE, Jung JK, Kim CJ, Park JS, Kim JW, Lee JM, Kim SJ (1997) Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 64: 418-424
2. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55: 2007-2011
3. Bradley SM, Douglas Y (2005) Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65: 10123-10127
4. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566
5. Chou CY, Wang ST, Kuo HC, Tzeng CC, Yao BL (1994) Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. Cancer 74: 2497-2501
6. Dal Maso L, Augustin LS, Franceschi S, Talamini R, Polesel J, Kendall CW, Jenkins DJ, Vidgen E, La Vecchia C (2004) Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology 67: 225-230
7. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-3616
8. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, Hoffma B, Hood N (2002) Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 74: 65-76
9. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, Pollak MN (2006) Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-396
10. Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43: 1895-1904
11. Hsu YM, Chou CY, Chen HH, Lee WY, Chen YF, Lin PW, Alper SL, Ellory JC, Shen MR (2007) IGF-1 upregulates electroneutral K-Cl cotransporter KCC3 and KCC4 which are differentially required for breast cancer cell proliferation and invasiveness. J Cell Physiol 210: 626-636
12. Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, Piao W, Nosho K, Arimura Y, Shinomura Y, Hosokawa M, Lee CT, Carbone DP, Imai K (2007) Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28: 947-956
13. Jones JL, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34
14. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625
15. Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT (2003) Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 91: 486-493
16. Muñoz N, Bosch FX, De Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
17. Peeters PH, Lukanova A, Allen N (2007) Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14: 81-90
18. Prager D, Li HL, Asa S, Melmed S (1994) Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 91: 2181-2185
19. Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, Mourits MJ, Nijman HW, Aalders JG, Hollema H, Pras E, Duk JM, van der Zee AG (2005) Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 23: 1455-1462
20. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353
21. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco EL, Biomarkers of Cervical Cancer Risk Study Team (2007) Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 16: 716-722
22. Schillaci R, Galeano A, Becu-Villalobos D, Spinelli O, Sapia S, Bezares RF (2005) Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. Br J Haematol 130: 58-66
23. Schips L, Zigeuner R, Ratschek M, Rehak P, Rüschoff J, Langner C (2004) Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. Am J Clin Pathol 122: 931-937
24. Schoell WM, Janicek MF, Mirhashemi R (1999) Epidemiology and biology of cervical cancer. Semin Surg Oncol 16: 203-211
25. Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A (1993) Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 268: 1087-1094
26. Serrano ML, Romero A, Cendales R, Sánchez-Gómez M, Bravo MM (2006) Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica 26: 258-268
27. Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY (2006) Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis 27: 962-971
28. Shen MR, Lin AC, Hsu YM, Chang TJ, Tang MJ, Alper SL, Ellory JC, Chou CY (2004) Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem 279: 40017-40025
29. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z (1996) Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56: 1761-1765
30. Syrjänen K, Kataja V, Yliskoski M, Chang F, Syrjänen S, Saarikoski S (1992) Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79: 675-682
31. Takeda M, Sakuragi N, Okamoto K, Todo Y, Minobe S, Nomura E, Negishi H, Oikawa M, Yamamoto R, Fujimoto S (2002) Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 81: 451-457
32. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828-832
33. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M (2003) Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 9: 3356-3361
34. Yu H, Rohan T (2000) Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489
35. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156
36. Yu K, Yoko FY (2007) An overview of currently available anti-insulin-like growth factor I receptor antibodies. BioScience Trends 1: 128-133
37. zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9-13